Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, ...

In this segment, Dr. Vachhani and Dr. Rampal discuss interferon therapy for polycythemia vera (PV), from early daily interferons to pegylated interferon alfa-2a (Pegasys) and the newer ropeginterferon ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

People will frown at you; they will mock you and will often tell you go to bed earlier and not sleep on the job.

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS ...

Takeda scores with polycythemia vera drug in phase 3 trial. A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...